THEMISMEDThemis Medicare Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, hematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasodilator, vasopressors, and vitamins. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on THEMISMED — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 24/100)
- • Revenue growth: -10.9% YoY
- • Profit growth: -96.2% YoY
- • RSI: 22
- • MACD: bearish
Bull case
- • Debt/Equity: 0.25
- • Promoter holding: 48.4%
- • Valuation vs sector: P/E 21.1 vs sector 35.5
- • Golden cross setup: SMA50 above SMA200
Bear case
- • Revenue growth: -10.9% YoY
- • Profit growth: -96.2% YoY
- • RSI: 22
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: -10.9% YoY
- • Profit growth: -96.2% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹6.32). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.